HDAC inhibitors are classified into four main subgroups based on their chemical composition: hydroxamic acids, benzamides, cyclic tetrapeptides, and short-chain fatty acids ( Table 2 ) ( Table 2 Introduction to the mechanism of action, trial phase, and FDA approval of HDACi
The typical journey looks like this: Weeks 1-4: The adjustment phase (most challenging) Weeks 4-8: Significant improvement Month 3+: Most people feel comfortable and confident But dont suffer in silence
In functional medicine, BPC-157 is often combined with other peptides (like TB-500 or Thymosin-1) or detox and support protocols to create a synergistic healing effect
This helps researchers overcome common experimental challenges with confidence
Specifically, the primary clinical limitation remains the absence of large-scale Randomized Controlled Trials (RCTs) in PAH patients, particularly those without diabetes